Benzinga | Oct 19, 2020 12:33PM EDT

Aegis Capital Maintains Buy on Biomerica, Lowers Price Target to $11

Aegis Capital maintains Biomerica (NASDAQ:BMRA) with a Buy and lowers the price target from $13 to $11.